•
Jun 30, 2020

TELA Bio Q2 2020 Earnings Report

Reported financial results, demonstrating resilience and flexibility amidst pandemic challenges.

Key Takeaways

TELA Bio reported a 6% increase in revenue to $3.5 million for Q2 2020, with a gross profit of $2.1 million, or 59% of revenue. The company's operating expenses were $7.3 million, leading to a net loss of $6.1 million. Cash and cash equivalents totaled $85.5 million at the end of the quarter.

Revenue increased by 6% compared to the prior year period, reaching $3.5 million.

Gross profit was $2.1 million, representing 59% of revenue.

Operating expenses increased to $7.3 million due to commercial expansion and public company costs.

Cash and cash equivalents totaled $85.5 million.

Total Revenue
$3.51M
Previous year: $3.3M
+6.2%
EPS
-$0.53
Previous year: -$0.811
-34.6%
Gross Profit
$2.1M
Previous year: $1.91M
+10.1%
Cash and Equivalents
$85.5M

TELA Bio

TELA Bio

Forward Guidance

Due to the uncertainty caused by the COVID-19 pandemic, TELA Bio will not be providing 2020 financial guidance.